SLFN11 and ovarian cancer: Our results should be further validated in studies based on a larger cohort of patients, in order to explore to a greater extent whether the DNA methylation of SLFN11 promoter could serve as a potential prognostic DNA methylation biomarker and a predictor of resistance to platinum-based chemotherapy in ovarian cancer.